Inhibikase Therapeutics, Inc.
IKT
$1.66
-$0.01-0.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -39.43% | -75.36% | -143.58% | -125.79% | -90.35% |
| Total Depreciation and Amortization | 47.38% | 129.55% | 154.55% | 89.77% | -81.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.05% | 150.06% | 6,263.35% | 5,377.67% | 3,434.39% |
| Change in Net Operating Assets | -263.20% | -72.73% | -176.93% | -7.27% | -68.59% |
| Cash from Operations | -84.39% | -45.11% | -48.54% | -20.86% | -21.31% |
| Capital Expenditure | 100.00% | -- | -- | -- | 5.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -688.03% | 105.58% | -10,119.60% | -137.56% | -188.92% |
| Cash from Investing | -687.19% | 105.55% | -10,123.35% | -137.65% | -189.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8.03% | 4.82% | 2,535.08% | 2,665.89% | 25,786.51% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -- | -177.85% | -- | 118.09% |
| Cash from Financing | 8.00% | 4.82% | 2,624.40% | 2,776.18% | 53,325.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -133.58% | 74.81% | 367.83% | 6,219.31% | 4,534.14% |